SCHEMBL1797495

SCHEMBL1797495

Cc1nc(-c2c[nH]c3ncc(C4CCC(N5CCN(C)CC5)CC4)cc23)cs1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK8 P45983 2/20 0.53
▸ MAPK9 P45984 2/20 0.53
▸ MAPK10 P53779 2/20 0.53
▸ MAP4K1 Q92918 2/20 0.39
▸ IL2 P60568 1/20 0.39
▸ IRAK4 Q9NWZ3 1/20 0.38
▸ TLR9 Q9NR96 2/20 0.36
▸ TLR7 Q9NYK1 2/20 0.36
▸ ROCK1 Q13464 2/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ GSK3B P49841 1/20 0.35
▸ DYRK1A Q13627 1/20 0.35
▸ TNIK Q9UKE5 3/20 0.34
▸ CDK2 P24941 2/20 0.34
▸ CCNT1 O60563 1/20 0.34
▸ CCNA2 P20248 1/20 0.34
▸ CDK9 P50750 1/20 0.34
▸ RET P07949 1/20 0.34
▸ MAP3K11 Q16584 3/20 0.33
▸ IKBKB O14920 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8172108 1.00 MAPK8 (0.53) MAPK8MAPK9MAPK10MAP4K1IL2
SCHEMBL1797497 1.00 MAPK8 (0.53) MAPK8MAPK9MAPK10MAP4K1IL2
SCHEMBL1801278 0.92 MAPK8 (0.54) MAPK8MAPK9MAPK10MAP4K1IL2
SCHEMBL1801276 0.92 MAPK8 (0.54) MAPK8MAPK9MAPK10MAP4K1IL2
SCHEMBL1798799 0.90 MAPK8 (0.64) MAPK8MAPK9MAPK10MAP4K1IL2
SCHEMBL1798802 0.90 MAPK8 (0.64) MAPK8MAPK9MAPK10MAP4K1IL2
SCHEMBL8168391 0.90 MAPK8 (0.64) MAPK8MAPK9MAPK10MAP4K1IL2
SCHEMBL1798767 0.89 MAPK8 (0.51) MAPK8MAPK9MAPK10MAP4K1IL2
SCHEMBL1798764 0.89 MAPK8 (0.51) MAPK8MAPK9MAPK10MAP4K1IL2
SCHEMBL1798440 0.87 MAPK8 (0.66) MAPK8MAPK9MAPK10MAP4K1IL2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951802-B2 Use of 7-azaindoles in the inhibition of c-Jun N-terminal kinase EISAI R&D MANAGEMENT CO., LTD. (JP) 2011-05-31 — — US disclosed
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-03-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069358-A1 USE OF 7-AZAINDOLES IN THE INHIBITION OF C-JUN N-TERMINAL KINASE MAPK7, MAPKAPK5, MAPK13 MAPK8 33/4885MAPK9 27/4885MAPK10 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback